Vaxigrip Tetra Special Precautions

Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.
VaxigripTetra should under no circumstances be administered intravascularly.
As with other vaccines administered intramuscularly, the vaccine should be administered with caution to subjects with thrombocytopaenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.
Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent injury from fainting and manage syncopal reactions.
VaxigripTetra is intended to provide protection against those strains of influenza virus from which the vaccine is prepared.
As with any vaccine, vaccination with VaxigripTetra may not protect all vaccinees.
Regarding passive protection, not all infants less than 6 months of age born to women vaccinated during pregnancy may be protected (see Pharmacology: Pharmacodynamics under Actions).
Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient.
Interference with serological testing: See Interactions.
VaxigripTetra contains potassium and sodium: This vaccine contains less than 1 mmol potassium (39 mg) and less than 1 mmol sodium (23 mg) per dose, that is to say it is essentially "potassium-free" and "sodium-free".
Effects on ability to drive and use machines: VaxigripTetra has no or negligible influence on the ability to drive and use machines.